title: Does sildenafil affect uroflowmetry values in men with lower urinary tract symptoms suggestive of benign prostatic enlargement?
abstract: OBJECTIVE
  To investigate the effect of sildenafil on uroflowmetry values of patients with lower urinary tract symptoms (LUTS) suggestive of benign prostatic enlargement (BPE).
  
  
  METHODS
  Thirty-eight consecutive patients and 15 control subjects without voiding symptoms were enrolled in the study. All patients underwent uroflowmetry testing thrice on different occasions. The highest maximum urinary flow rate (Q(max)) values with a sufficient voided volume (> or =150 ml) were evaluated. The patients and controls were seen the day after the initial uroflowmetry measurements and were given 100 mg sildenafil. Afterwards uroflowmetry was repeated. The uroflowmetry values of both groups before and after sildenafil were compared.
  
  
  RESULTS
  Of the 38 patients, 29 (76%) showed improvement in flow rates. The mean Q(max) was 11.4 +/- 0.39 and 15.7 +/- 0.74 ml/s before and after sildenafil, respectively (p < 0.0001). The mean percentage difference in Q(max) was +38% higher after sildenafil. The mean average flow rate (Q(ave)) and the mean voiding time values were also significantly improved. The mean voided volumes of the patients before and after sildenafil were 241 +/- 78 and 264 +/- 72 ml, respectively (p = 0.07). There were no significant differences in the Q(max), Q(ave) and voided volumes of the control group.
  
  
  CONCLUSIONS
  Sildenafil exhibits a significant improvement in Q(max) and Q(ave) rates in men with LUTS.
authors: Department of Urology, Afyon Kocatepe University School of Medicine, Afyon, Turkey.
authors: Cem
authors: C
authors: Güler
authors: Emre
authors: E
authors: Tüzel
authors: Engin
authors: E
authors: Doğantekin
authors: Güneş
authors: G
authors: Kiziltepe
mesh_terms: D000368:Aged; D006801:Humans; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D010865:Pilot Projects; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000150:complications / Q000503:physiopathology*; D053448:Prostatism / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology*; D011687:Purines / Q000494:pharmacology / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000494:pharmacology / Q000627:therapeutic use*; D014563:Urodynamics / Q000187:drug effects*
chemical_list: D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate